Vaxart Secures $3,500,000 New Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1ae567b4-ff4e-49f7-9437-b496f8c31672&Preview=1 -
Date
1/15/2010 -
Company Name
Vaxart -
Mailing Address
600 Townsend St San Francisco, CA 94103 -
Company Description
The combination of adenovirus vector, adjuvant and oral administration will unlock the potential of vector-based vaccination, with applications in Avian Influenza response, biodefense vaccines, and second-generation versions of existing vaccines. The company is currently testing an avian flu vaccine. -
Website
http://www.vaxart.com -
Transaction Type
Venture Equity -
Transaction Amount
$3,500,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds purposes were not disclosed. -
M&A Terms
-
Venture Investor
Undisclosed
